Gland Pharma zooms despite reporting 16% fall in Q2 consolidated net profit
Gland Pharma is currently trading at Rs. 1814.85, up by 205.00 points or 12.73% from its previous closing of Rs. 1609.85 on the BSE.
The scrip opened at Rs. 1600.00 and has touched a high and low of Rs. 1824.20 and Rs. 1600.00 respectively. So far 60279 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 2220.95 on 06-Aug-2024 and a 52 week low of Rs. 1503.70 on 06-Nov-2023.
Last one week high and low of the scrip stood at Rs. 1824.20 and Rs. 1600.00 respectively. The current market cap of the company is Rs. 29342.28 crore.
The promoters holding in the company stood at 51.83%, while Institutions and Non-Institutions held 39.84% and 8.32% respectively.
Gland Pharma has reported 9.39% rise in its net profit at Rs 281.71 crore for second quarter ended September 30, 2024 (Q2FY25) as compared to Rs 257.53 crore for the same quarter in the previous year. Total income of the company increased by 6.56% at Rs 1,120.79 crore for Q2FY25 as compared to Rs 1,051.78 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported 15.74% fall in net profit at Rs 163.53 crore for Q2FY25 as compared to Rs 194.08 crore for the same quarter in the previous year. However, total income of the company increased by 2.73% at Rs 1,465.49 crore for Q2FY25 as compared to Rs 1,426.58 crore for the corresponding quarter previous year.